 As to the second point, standard-type remission induction therapy is ineffective in 20 or more of the patients, whereas the application of the more effective postremission consolidation options alloSCT, high-dose cytarabine courses is often flawed by high-grade toxicity which can offset expected benefits, particularly in older age groups 50-55 years, where therapy-related death rates are seen in 5-10 of the cases chemotherapy or more transplants. 